60 Degrees Pharmaceuticals Announces ARAKODA Promotional Pilot In Advance Of Expanded U.S. Launch Indicated For The Prevention Of Malaria In Patients Aged 18 Years And Older
60 Degrees Pharmaceuticals Announces ARAKODA Promotional Pilot In Advance Of Expanded U.S. Launch Indicated For The Prevention Of Malaria In Patients Aged 18 Years And Older
60度制药公司宣布在美国扩大上市前推出ARAKODA促销试点，专为18岁及以上患者预防疟疾。
- Highlights include increased ARAKODA (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs.
- ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile.
- 通过使用数字行为分析和共付计划，利用虚拟销售推广提高ARAKODA（替诺奎宁）品牌知名度和利用率，以帮助消费者支付自费费用。
- ARAKODA是十年来唯一的新抗疟药，其特点在于针对所有疟疾阶段的广泛疗效、方便的每周服药时间表和良好的安全性记录。
WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company has commenced a nine-month promotional pilot to bring greater awareness of ARAKODA (tafenoquine) and its benefits to patients and healthcare providers who prescribe it.
2024年10月03日华盛顿（GLOBE NEWSWIRE）——60 Degrees Pharmaceuticals, Inc.（纳斯达克：SXTP；SXTPW）（“公司”），一家专注于开发用于传染病的新药品的药品公司，今天宣布该公司已启动为期九个月的促销试点项目，以向为其患者和开具处方的医疗保健提供者提供更广泛对ARAKODA（替诺奎宁）及其益处的认识。
ARAKODA (tafenoquine) is an antimalarial indicated for the prevention of malaria in patients aged 18 years and older.
ARAKODA（替诺奎宁）是一种抗疟药，适用于18岁及以上患者的疟疾预防。